First Tracks Biotherapeutics director Magda Marquet exercised restricted stock units into common shares. On June 15, 2026, she converted 6,030 restricted stock units into 6,030 shares of common stock for no cash consideration, reflecting compensation rather than a market purchase or sale.
Following the transaction, she directly owns 15,960 shares of common stock. The RSU award vested 100% on June 15, 2026, contingent on her continued service to the company through that date.
First Tracks Biotherapeutics director Dennis M. Fenton exercised restricted stock units into common shares as part of his equity compensation. On June 15, 2026, 6,030 RSUs converted into 6,030 shares of common stock at no cash cost, bringing his direct holdings to 10,995 shares. The RSUs vested in full on that date, with no remaining RSU balance reported.
First Tracks Biotherapeutics director Dennis M. Fenton received new equity awards. On May 12, 2026, he was granted stock options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting monthly over one year starting June 12, 2026.
He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest in full at the company’s 2027 annual meeting of shareholders, if he continues providing service through that date.
First Tracks Biotherapeutics director Rita Jain received new equity awards. On May 12, 2026, she was granted options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting monthly over one year starting June 12, 2026. She also received 2,500 restricted stock units, each convertible into one share of common stock, which vest in full on the date of the company’s 2027 annual meeting of shareholders, in both cases contingent on continued service.
First Tracks Biotherapeutics, Inc. director Magda Marquet received equity-based compensation awards. She was granted stock options for 7,000 shares of common stock at an exercise price of 17.81 per share, expiring on May 11, 2036, and 2,500 restricted stock units. The options vest in 12 equal monthly installments starting June 12, 2026, while all RSUs vest on the date of the company’s 2027 annual shareholders meeting, in each case subject to continued service.
First Tracks Biotherapeutics director equity grants: Director John A. Orwin received stock options for 7,000 shares of Common Stock at an exercise price of $17.81 per share and 2,500 Restricted Stock Units on May 12, 2026, as compensation awards, not open‑market trades.
The 2,500 RSUs each represent one share of Common Stock for no cash cost and vest 100% on the date of the company’s 2027 annual shareholder meeting, if he continues serving the company. The 7,000 stock options vest in 12 equal monthly installments starting June 12, 2026, through full vesting, also conditioned on continued service.
First Tracks Biotherapeutics director John P. Schmid received new equity awards as part of his compensation. On May 12, 2026, he was granted stock options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting in equal monthly installments over 12 months starting June 12, 2026. He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment, which vest in full on the date of the company’s 2027 annual meeting of shareholders, as long as he continues to provide service to the company.
First Tracks Biotherapeutics director Ware J. Anthony reported new equity compensation awards. On May 12, 2026, he received stock options covering 7,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest in equal monthly installments, with 1/12 of the total vesting each month starting June 12, 2026, as long as he continues serving the company.
He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest 100% on the date of First Tracks’ 2027 annual meeting of shareholders, subject to his continued service.
First Tracks Biotherapeutics supplements its prospectus to register the resale by selling stockholders of up to 10,497,054 shares of common stock. The Company states it will not receive any proceeds from the sale of these Resale Shares. The prospectus supplement incorporates the Company's Form 10-Q for the quarter ended March 31, 2026. Shares outstanding were 34,892,381 as of May 12, 2026.
First Tracks Biotherapeutics, Inc. registers 10,497,054 shares of common stock for resale by selling stockholders, with no proceeds payable to the company from the resale. The registration covers resale of shares issued in a March 26, 2026 private placement, which included 5,791,479 Primary Shares and 4,705,575 Secondary Shares. The Private Placement generated approximately $80 million of gross proceeds to the company from the Primary Shares. The prospectus states the selling stockholders may sell at prevailing market prices or in privately negotiated transactions; the prospectus date is May 14, 2026 and the Nasdaq closing price on May 13, 2026 was $18.43 per share.